The GoodRx Prescription Savings Blog

The latest updates on prescription drugs and ways to save from the GoodRx medical team

New Insulin Basaglar in Pharmacies This Year

by Roni Shye on February 17, 2016 at 3:50 pm

Basaglar (insulin glargine) is the newest brand of long-acting insulin to hit the market. It shares its active ingredient (insulin glargine) with Lantus, but is not a generic equivalent and the two can’t be substituted for each other.

Long-acting insulin like Basaglar (also sometimes referred to as basal insulin) are used to keep blood glucose levels stable throughout the day.

There are now four long-acting insulins approved by the FDA: Lantus, Levemir (insulin detemir), Toujeo (insulin glargine recombinant), Tresiba (insulin degludec), and Basaglar.

Is there anything unique about Basaglar?

Yes. Basaglar has been available in Europe, Canada, Columbia, Japan, and Australia as a new insulin glargine biosimilar to Lantus. It’s now on its way to the US.

Does that mean Basaglar can be substituted for Lantus at the pharmacy?

No. In the US, Basaglar was approved as a new drug, which means it has to prescribed by your doctor—or approved as a new prescription if you switch from Lantus. Although both Basaglar and Lantus are both insulin glargine they cannot be automatically substituted for one another without your doctor’s approval.

How is Basaglar used?

Dosing with Basaglar is individualized and will be determined by your doctor—not everyone will use the same amount. Basaglar is injected once-daily at any time of the day (but should be used at the same time every day).

How will Basaglar be available?
Basaglar is a solution for injection (100 units/mL) in a box of five 3 mL prefilled KwikPens.

What are the side effects of Basaglar?

The most common side effects associated with Basaglar are low blood sugar, allergic reactions, injection site reactions, itching, rash, and retaining water.

When was Basaglar approved?
Basaglar was approved by the FDA on December 16, 2015.

When will Basaglar be available?
Basaglar will be available in the U.S. in December 2016.

Want more information?

Check out the the press announcement from the manufacturer Eli Lilly here and see the announcement from the FDA here.

Copyright ©2015 GoodRx, Inc.

This information is for informational purposes only and is not meant to be a substitute for professional medical advice, diagnosis or treatment. GoodRx is not offering advice, recommending or endorsing any specific prescription drug, pharmacy or other information on the site. GoodRx provides no warranty for any of the pricing data or other information. Please seek medical advice before starting, changing or terminating any medical treatment. Third party logos, trademarks, brand names and images contained on are for demonstration purposes only and are owned by their respective rights holders, who are not affiliated with this Site.